Certification in Specialty Pharmacy Exam - Preparation Course

Activity Description

Specialty pharmacy is the fastest growing segment of pharmacy practice today and will continue for the foreseeable future. Specialty pharmacy impacts only a small percent of the population; however, the diseases and drug therapies are very complex and require a higher level of knowledge compared to more traditional diseases and drug therapies. The Certified Specialty Pharmacist Credential is designed to validate your professional expertise, elevate the status of the specialty pharmacy profession, differentiate yourself in a competitive job market, position yourself for handling limited or exclusively distributed drugs, position yourself to better serve payer requirements, and protect the public by improving their health outcomes and reducing medication errors.

The CSP Exam Preparatory Course will cover aspects of Clinical, Fulfillment, Intake and Outcomes that might be expected on the exam. Join expert faculty as key aspects of specialty pharmacy and the specialty pharmacist’s role are discussed. Key topics include the fundamentals and considerations for the patient intake process, as well as fulfillment workflows, quality assurance and dispensing channels. Outcomes measures and standards are covered, and clinical modules review persistence and adherence, specialty drug classes, indications, interactions, and more.

Learning Objectives

The target audience for this activity includes pharmacists.

At the completion of Inflammatory Diseases, participants will be able to:
  • Distinguish which class each specialty medication used to treat inflammatory conditions belongs to.
  • Discuss storage recommendations, routes of administration, and standard doses for various indications of specialty medications used to treat inflammatory conditions.
  • Identify associated adverse effects and warnings of specialty medications used to treat inflammatory conditions.
At the completion of Oncology, participants will be able to:
  • Describe the general principles of cancer pathophysiology.
  • Identify the most common oral oncology agents utilized in clinical practice.
  • List oral oncology agents by mechanism of action.
  • Explain the indication, dosing, and common side effects with the oral oncology agents.
At the completion of Hepatitis , participants will be able to:
  • Describe the epidemiology and pathophysiology of hepatitis C virus (HCV).
  • List current HCV treatment options and discuss monitoring parameters.
  • Outline the appropriate HCV treatment strategies based on patient characteristics.
  • Identify common drug/drug interactions with direct acting antivirals (DAAs).
At the completion of Multiple Sclerosis, participants will be able to:
  • Differentiate the disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS).
  • Identify both common and serious adverse effects, as well as significant drug/drug interactions for each DMT.
  • Identify recommended monitoring parameters for each DMT, including Risk Evaluation and Mitigation Strategy (REMS) requirements.
  • Explain how each product is supplied and how to properly administer as well as store each DMT.
At the completion of HIV, participants will be able to:
  • Discuss medications from various classes of antiviral agents used to treat HIV.
  • Discuss the mechanism of action for each class of medications.
  • Discuss recommended protocols and be able to assess a treatment plan for clinical appropriateness.
  • Explain the limitations and considerations of various medications based on patient-specific characteristics.
At the completion of Hemophilia, participants will be able to:
  • Discuss the etiology of hemophilia.
  • Explain appropriate treatment options based on specific hemophilia diagnosis.
  • Discuss considerations in dispensing factor prescriptions.
At the completion of Immunoglobulin (Ig) Therapy, participants will be able to:
  • Discuss the role of immunoglobulin (Ig) therapy in the treatment of immune-deficient patients.
  • Explain the proposed mechanism of action of immunoglobulin therapy.
  • Discuss risk factors for adverse events associated with Ig.
  • Compare and contrast available Ig products.
  • Review appropriate factors when evaluating Ig products.
At the completion of Intake, Clinical Management, Outcomes & Fulfillment, participants will be able to:
  • Outline and explain key considerations for the specialty pharmacist concerning the patient intake process.
  • List the required information that must be obtained for each patient.
  • Discuss the key components required in the clinical management of a patient.
  • Review various ways to monitor patient outcomes.
  • Discuss the patient fulfillment process.

Faculty

Aimee Banks, PharmD, BCPS (Multiple Sclerosis)
Clinical Pharmacist, Multiple Sclerosis Clinic
Vanderbilt University Medical Center

Jeff Engle, PharmD, MS (Oncology)
Oncology/Hematology Clinical Pharmacist
Fairview Specialty Pharmacy
University of Minnesota Masonic Cancer Clinic

April Jones, PharmD, CSP (Inflammatory Diseases)
Clinical Pharmacist, Specialty Pharmacy Services
Vanderbilt University Medical Center

Kanika Kapoor, PharmD, CSP (Intake, Clinical Management, Outcomes & Fulfillment)
Clinical Pharmacist, Diplomat Pharmacy

Brandon M. Markley, PharmD, BCPS (Multiple Sclerosis)
Clinical Pharmacist, Vanderbilt University Medical Center
Multiple Sclerosis Clinic

Kevn McNamara, PharmD (Hemophilia, Immunoglobulin (Ig) Therapy. Intake, Clinical Management, Outcomes & Fulfillment)
Owner-Manager, Clinical Pharmacy Partners

Jackie Senogles, PharmD, CSP (Intake, Clinical Management, Outcomes & Fulfillment)
Fairview Pharmacy Services

Melissa (Mel) Nelson, PharmD, CSP (Intake, Clinical Management, Outcomes & Fulfillment)
Specialty Pharmacy Manager, Fairview Pharmacy Services

Erin Stack Mellerski, PharmD (Hemophilia, Immunoglobulin (Ig) Therapy)
Supervising Pharmacist, Cottrill’s Specialty Pharmacy

Kristen Whelchel, PharmD (HIV, Hepatitis)
Vanderbilt Specialty Pharmacy

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. None of the speakers have any relevant commercial or financial relationships to disclose.

Please note: The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.

CE Accreditation

Release Date: 07-10-2019
Expiration Date: 07-10-2022

Pharmacists

This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Numbers 0221-9999-19-276-H01-P, 0221-9999-19-277-H01-P, 0221-9999-19-278-H01-P, 0221-9999-19-279-H01-P, 0221-9999-19-280-H01-P, 0221-9999-19-281-H01-P, 0221-9999-19-282-H01-P, 0221-9999-19-283-H04-P have been assigned to these knowledge-based home-study CE activities (initial release date 07-10-19). These activities (8 individual activities) are approved for a maximum of 5.8 total contact hours (0.58 CEU) in states that recognize ACPE providers. Completion of the evaluations and the post-tests with a score of 70% or higher are required to receive CE credit. No partial credit will be given.

Funding

No external support has been received for this activity.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.